Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study (GPCBasedow)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02798965
Recruitment Status : Completed
First Posted : June 14, 2016
Last Update Posted : June 16, 2016
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.

Condition or disease Intervention/treatment Phase
Graves Disease Biological: serodiagnosis Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study
Study Start Date : December 2010
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Control
patients with goiter or nodule
 Biological: serodiagnosis
Experimental: Graves' disease
patients with Graves' disease
 Biological: serodiagnosis


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. prevalence of circulating parvovirus genome [ Time Frame: Day 0 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months
  • Control : patients cared for nodules or goiter

Exclusion Criteria:

  • Patients undergoing immunosuppressive therapy including corticosteroids
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02798965


Locations
Layout table for location information
France
CHU Amiens
Amiens, France, 80054
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Investigators
Layout table for investigator information
Principal Investigator: Rachel DESAILLOUD, MD, PhD CHU Amiens
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT02798965    
Other Study ID Numbers: AOL10-DR-DESAILLOUD
First Posted: June 14, 2016    Key Record Dates
Last Update Posted: June 16, 2016
Last Verified: June 2016
Keywords provided by Centre Hospitalier Universitaire, Amiens:
parvovirus genome
Additional relevant MeSH terms:
Layout table for MeSH terms
Parvoviridae Infections
Graves Disease
Exophthalmos
Orbital Diseases
Eye Diseases
Goiter
Thyroid Diseases
 Endocrine System Diseases
Hyperthyroidism
Autoimmune Diseases
Immune System Diseases
DNA Virus Infections
Virus Diseases